NASDAQ:BMRA Biomerica (BMRA) Stock Price, News & Analysis $3.12 -0.06 (-1.89%) Closing price 03:55 PM EasternExtended Trading$3.17 +0.05 (+1.73%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biomerica Stock (NASDAQ:BMRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biomerica alerts:Sign Up Key Stats Today's Range$3.06▼$3.2850-Day Range$3.11▼$5.6852-Week Range$1.93▼$10.16Volume6,267 shsAverage Volume276,879 shsMarket Capitalization$7.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBiomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Read More… Biomerica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreBMRA MarketRank™: Biomerica scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Biomerica. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomerica is -9.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomerica is -9.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomerica has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.65% of the float of Biomerica has been sold short.Short Interest Ratio / Days to CoverBiomerica has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biomerica has recently decreased by 11.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomerica does not currently pay a dividend.Dividend GrowthBiomerica does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.65% of the float of Biomerica has been sold short.Short Interest Ratio / Days to CoverBiomerica has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biomerica has recently decreased by 11.86%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.39 News SentimentBiomerica has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Biomerica this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomerica insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.28% of the stock of Biomerica is held by institutions.Read more about Biomerica's insider trading history. Receive BMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRA Stock News HeadlinesBiomerica's inFoods® IBS Demonstrates Significant Reductions in GI Pain and Bloating in Real-World StudyMay 24, 2025 | nasdaq.comBiomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback SystemMay 22, 2025 | globenewswire.comTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?May 28, 2025 | Augusta Precious Metals (Ad)Biomerica Submits PLA Code Application to Enhance Patient Access to inFoods® IBS Diagnostic TestMay 9, 2025 | nasdaq.comPLA Code Application Filed for inFoods IBS Test - A Key Step Toward ReimbursementMay 7, 2025 | tmcnet.comPLA Code Application Filed for inFoods IBS Test — A Key Step Toward ReimbursementMay 7, 2025 | globenewswire.comBiomerica announces Fortel Ulcer Test approved for sale by UAE MinistryApril 24, 2025 | markets.businessinsider.comUnited Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Detection of H. pylori InfectionApril 23, 2025 | globenewswire.comSee More Headlines BMRA Stock Analysis - Frequently Asked Questions How have BMRA shares performed this year? Biomerica's stock was trading at $2.4008 at the start of the year. Since then, BMRA stock has increased by 30.0% and is now trading at $3.12. View the best growth stocks for 2025 here. How were Biomerica's earnings last quarter? Biomerica, Inc. (NASDAQ:BMRA) released its quarterly earnings results on Monday, April, 14th. The company reported ($0.48) earnings per share (EPS) for the quarter. The company had revenue of $1.12 million for the quarter. Biomerica had a negative trailing twelve-month return on equity of 90.19% and a negative net margin of 100.52%. When did Biomerica's stock split? Biomerica's stock reverse split before market open on Monday, April 21st 2025. The 1-8 reverse split was announced on Wednesday, April 16th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. Who are Biomerica's major shareholders? Biomerica's top institutional investors include Bulltick Wealth Management LLC (5.39%), Granahan Investment Management LLC (3.46%) and Simplex Trading LLC. Insiders that own company stock include Zackary S Irani, Allen Barbieri and Catherine Coste. View institutional ownership trends. How do I buy shares of Biomerica? Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomerica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), Exxon Mobil (XOM), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings4/14/2025Today5/28/2025Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMRA CIK73290 Webwww.biomerica.com Phone(949) 645-2111Fax949-553-1231Employees60Year Founded1971Profitability EPS (Most Recent Fiscal Year)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.98 million Net Margins-100.52% Pretax Margin-100.31% Return on Equity-90.19% Return on Assets-64.54% Debt Debt-to-Equity RatioN/A Current Ratio3.17 Quick Ratio2.22 Sales & Book Value Annual Sales$5.68 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book8.40Miscellaneous Outstanding Shares2,546,000Free Float15,586,000Market Cap$8.34 million OptionableOptionable Beta0.37 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:BMRA) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.